Literature DB >> 8656046

Interleukin-12 protects thermally injured mice from herpes simplex virus type 1 infection.

R Matsuo1, M Kobayashi, D N Herndon, R B Pollard, F Suzuki.   

Abstract

Severe burn injury is associated with increased susceptibility to severe herpesvirus infections. Type 2 cytokines [interleukin (IL)-4 and IL-10] released from burn-associated CD8+ type 2 T cells (BA-type 2 T cells) have been shown to play a role in the increased susceptibility of thermally injured mice (TI-mice) to herpes simplex virus type 1 (HSV-1) infection. Because IL-12 has been shown to inhibit the generation of type 2 T cells, murine rIL-12 was injected into TI-mice exposed to HSV-1 to determine whether IL-12 could influence HSV-1 infections in individuals bearing type 2 T cells. rIL-12 improved the resistance of TI-mice or mice inoculated with T6S cells (a BA-type 2 T cell clone) against HSV-1 infection. Type 2 cytokines were detected in sera of TI-mice or mice inoculated with T6S cells (T6S-mice). However, treatment of TI-mice or T6S-mice with rIL-12 inhibited type 2 cytokine production in the sera of these mice. All TI-mice exposed to a lethal dose of HSV-1 survived when they were treated with a mixture of monoclonal antibodies (mAbs) against type 2 cytokines. Staphylococcal enterotoxin A [an interferon-gamma (IFN-gamma) inducer] stimulated serum IFN-gamma production in TI-mice and T6S-mice treated with rIL-12, whereas no IFN-gamma was produced in mice treated with saline. These results suggest that IL-12 has the potential to protect TI-mice infected with a lethal dose of HSV-1 via a shift to type 1 T cell responses from type 2 T cell responses.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8656046     DOI: 10.1002/jlb.59.5.623

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  11 in total

1.  Effects of glycyrrhizin, an active component of licorice roots, on Candida albicans infection in thermally injured mice.

Authors:  T Utsunomiya; M Kobayashi; D N Herndon; R B Pollard; F Suzuki
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

2.  Endogenous interleukin-12 is not required for resolution of Chlamydophila abortus (Chlamydia psittaci serotype 1) infection in mice.

Authors:  L Del Río; A J Buendía; J Sánchez; M C Gallego; M R Caro; N Ortega; J Seva; F J Pallarés; F Cuello; J Salinas
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

3.  Interleukin-12 exhibits potent antiviral activity in experimental herpesvirus infections.

Authors:  J A Carr; J Rogerson; M J Mulqueen; N A Roberts; R F Booth
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma.

Authors:  Richard F Little; James M Pluda; Kathleen M Wyvill; Isaac R Rodriguez-Chavez; Giovanna Tosato; Andrew T Catanzaro; Seth M Steinberg; Robert Yarchoan
Journal:  Blood       Date:  2006-02-28       Impact factor: 22.113

5.  Reversal of ultraviolet radiation-induced immune suppression by recombinant interleukin-12: suppression of cytokine production.

Authors:  D A Schmitt; J P Walterscheid; S E Ullrich
Journal:  Immunology       Date:  2000-09       Impact factor: 7.397

Review 6.  Interleukin-12 in infectious diseases.

Authors:  L Romani; P Puccetti; F Bistoni
Journal:  Clin Microbiol Rev       Date:  1997-10       Impact factor: 26.132

Review 7.  Interleukin 12 a key immunoregulatory cytokine in infection applications.

Authors:  Therwa Hamza; John B Barnett; Bingyun Li
Journal:  Int J Mol Sci       Date:  2010-02-26       Impact factor: 5.923

8.  Appearance of monocyte chemoattractant protein 1 (MCP-1) early after thermal injury: role in the subsequent development of burn-associated type 2 T-cell responses.

Authors:  Katsunori Furukawa; Makiko Kobayashi; David N Herndon; Richard B Pollard; Fujio Suzuki
Journal:  Ann Surg       Date:  2002-07       Impact factor: 12.969

9.  Recombinant human growth hormone modulates Th1 and Th2 cytokine response in burned mice.

Authors:  K Takagi; F Suzuki; R E Barrow; S E Wolf; D N Herndon
Journal:  Ann Surg       Date:  1998-07       Impact factor: 12.969

10.  Phase 2 study of pegylated liposomal doxorubicin in combination with interleukin-12 for AIDS-related Kaposi sarcoma.

Authors:  Richard F Little; Karen Aleman; Pallavi Kumar; Kathleen M Wyvill; James M Pluda; Elizabeth Read-Connole; Victoria Wang; Stefania Pittaluga; Andrew T Catanzaro; Seth M Steinberg; Robert Yarchoan
Journal:  Blood       Date:  2007-09-10       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.